Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview

10592studies shown

Showing 8,821-8,832 of 10,592

Drug study icon

CompletedNCT00628420

Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics

This study is completed in the United States. It focuses on Schizophrenia.

In United States

SchizophreniaDrugFrom 20 Years to 50 Years

Countries: United States
Sponsor: University of Texas Southwestern Medical Center
Condition: Schizophrenia

Drug study icon

CompletedNCT00634439

Safety Study of Atomoxetine and Cerebrovascular Outcomes

This summary needs review. Please check the official study record and contact the research team for details.

In United States

ADHDDrugOver 18 Years

Countries: United States
Sponsor: Eli Lilly and Company
Condition: ADHD

Drug study icon

WithdrawnNCT01075126

Safety Study of Depakote Versus Lithium in African Americans With Bipolarity

This summary needs review. Please check the official study record and contact the research team for details.

In United States

BipolarityDrugFrom 18 Years to 60 Years

Countries: United States
Sponsor: Lawson, William B., M.D., PhD, DFAPA
Condition: Bipolarity

Drug study icon

CompletedNCT00829777

Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects

This summary needs review. Please check the official study record and contact the research team for details.

In United States

AddictionDrugFrom 21 Years to 45 Years

Countries: United States
Sponsor: California Pacific Medical Center Research Institute
Condition: Addiction

Drug study icon

CompletedNCT00190749

Safety Study of Olanzapine and a Comparator in people with Schizophrenia and Schizoaffective Disorder

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Eli Lilly and Company
Condition: Schizophrenia

Drug study icon

CompletedNCT02155829

Safety Study of Riluzole to Treat PTSD (PTSD)

This summary needs review. Please check the official study record and contact the research team for details.

In United States

PTSDDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Uniformed Services University of the Health Sciences
Condition: PTSD

Drug study icon

CompletedNCT00216294

Safety Study of the Drug RG1068 in people with OCD

This summary needs review. Please check the official study record and contact the research team for details.

In United States

OCDDrugFrom 18 Years to 40 Years

Countries: United States
Sponsor: Indiana University
Condition: OCD

Other study type icon

CompletedNCT01805518

Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals

This summary needs review. Please check the official study record and contact the research team for details.

Broader result

SuicidalityOtherFrom 45 Years to 65 Years

Countries: United States
Sponsor: Woodbury, Michel, M.D.
Condition: Suicidality

Drug study icon

CompletedNCT00490542

Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State

This study exists to explore whether the medication Ziprasidone could improve care and understanding. Researchers are trying to understand whether the medication Ziprasidone can give earlier or clearer feedback during care.

In United States

Depression, BipolarityDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Tufts Medical Center
Condition: Depression, Bipolarity

Behavioral study icon

Enrolling By InvitationNCT06460220

SAFETY-Parent: Online Learning Module to Support Parents of Suicidal Youth

This summary needs review. Please check the official study record and contact the research team for details.

Remote / online

SuicidalityBehavioralFrom 10 Years to 18 Years

Countries: United States
Sponsor: Jennifer Hughes
Condition: Suicidality

Drug study icon

CompletedNCT04822883

Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

This study exists to better understand the safety of the medication RL-007 and how manageable it feels in practice. Researchers are trying to understand whether the medication RL-007 can improve attention, thinking, or day-to-day functioning.

In United States

SchizophreniaDrugFrom 18 Years to 50 Years

Countries: United States
Sponsor: Recognify Life Sciences
Condition: Schizophrenia

Drug study icon

CompletedNCT00247572

Safety study of Intravenous NRP104 in Addiction

This study is completed in the United States. It is testing Intravenous NRP104 for Addiction.

In United States

AddictionDrugFrom 18 Years to 55 Years

Countries: United States
Sponsor: New River Pharmaceuticals
Condition: Addiction

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.